特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
953891

次世代癌診断:技術および世界市場

Next Generation Cancer Diagnostics: Technologies and Global Markets

出版日: | 発行: BCC Research | ページ情報: 英文 318 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.81円
次世代癌診断:技術および世界市場
出版日: 2020年08月11日
発行: BCC Research
ページ情報: 英文 318 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の次世代癌診断市場規模は、2020年の62億米ドルから、2025年までに167億米ドルへ拡大すると予測され、2020年から2025年の期間中は、21.9%のCAGRが見込まれています。消化器系の次世代癌診断市場規模は、2020年の15億米ドルから、2025年までに45億米ドルへ拡大すると予測され、2020年から2025年の期間中は、24.5%のCAGRが見込まれています。乳癌の次世代癌診断市場規模は、2020年の16億米ドルから、2025年までに31億米ドルへ拡大すると予測され、2020年から2025年の期間中は、13.9%のCAGRが見込まれています。

当レポートでは、世界の次世代癌診断市場について調査し、市場の概要 、市場規模データとCAGRの予測、世界市場の動向分析、主な取り組みとプログラム、技術・癌の部位別による分析、および主要企業のプロファイルなどを提供しています。

第1章 イントロダクション

  • 研究の目標と目的
  • 調査理由
  • レポートの範囲
  • 情報ソース
  • 調査手法
  • 地理的内訳
  • アナリストの経歴
  • BCCカスタム調査
  • BCC Research 関連レポート

第2章 サマリーとハイライト

第3章 概要

  • 大規模イニシアチブとコンソーシアム
  • 市場規模
  • 市場の原動力としてのリキッドバイオプシー
  • 主な動向
  • 業界

第4章 技術

  • 診断の概要
  • アレイおよびマイクロフルイディクス(LOAC)技術
  • DNAマイクロアレイ
  • タンパク質マイクロアレイ
  • マイクロフルイディクス
  • マルチプレックス従来技術
  • 次世代シーケンス技術
  • ポリメラーゼ連鎖反応(PCR)技術

第5章 リキッドバイオプシー技術

  • リキッドバイオプシーバイオマーカー
  • 癌ゲノミクス
  • 循環腫瘍細胞技術
  • CTCワークフロー
  • 細胞分離技術
  • CTCサンプル前処理技術
  • CTCダウンストリーム分析技術
  • 液体生検と従来の生検の比較
  • 癌検査
  • アバター主導の診断アプローチ

第6章 次世代癌診断:主な取り組みとプログラム

  • Blood Profiling Atlas
  • Cancer-ID
  • Cancer Moon Shots
  • China Precision Medicine Initiative
  • ClinGen
  • CTC Trap Consortium
  • Early Cancer Detection Consortium
  • EpiFemCare
  • France Genomic Medicine Plan
  • Friends of Cancer Research Project
  • Human Cell Atlas
  • Immunomonitor Consortium
  • Integration of Imaging and Fluid-Based Tumor Monitoring
  • Liquid Biopsies and Imaging for Improved Cancer Care
  • Million Veteran Program
  • MedSeq
  • Next-Generation Single-Cell Analysis Program
  • Population Sequencing Projects
  • Precancer Atlas
  • Precision Medicine Initiative
  • Prompt
  • QuIP Project
  • Single-Cell Proteomics and Lipidomics Project
  • TopMed
  • Treehouse Childhood Cancer Initiative
  • Very Rare Cancer Consortium
  • Worldwide Innovative Networking (WIN) Consortium
  • Single-Cell Research
  • Cambridge Single-Cell Analysis Core Facility
  • Harvard Medical School Single-Cell Core
  • Mayo Medical Genome Facility
  • National Center for Single-Cell Biology
  • Single-Cell Analysis Core
  • UC San Francisco Single-Cell Analysis Center
  • Population Sequencing Programs

第7章 次世代癌診断アプリケーション:癌の部位別

  • イントロダクション
  • 膀胱癌
  • 脳癌
  • 乳癌
  • 乳癌検診
  • 予後および薬理遺伝学検査
  • 乳癌MDxプラットフォーム
  • 次世代乳癌検査の状況
  • 乳癌の早期発見とスクリーニング検査
  • 乳癌リスク検査
  • 化学療法、再発確率、サブタイピングへの反応
  • 婦人科癌
  • 子宮頸癌
  • 卵巣癌
  • 大腸癌
  • 従来の大腸癌スクリーニング検査
  • 次世代の大腸癌の診断検査
  • 原発不明癌
  • 胃癌
  • 腎臓癌
  • 血液検査:白血病と骨髄腫
  • 肝臓癌
  • 肺癌
  • 血液検査:リンパ腫
  • 黒色腫
  • 汎癌
  • 前立腺癌
  • 甲状腺癌

第8章 癌診断産業

  • シーケンス機器業界
  • ロングリードシーケンシング産業
  • シーケンシング情報産業
  • PCR産業
  • 液滴デジタルPCR産業
  • CTCキャプチャおよび検出産業
  • 液体生検アッセイ産業

第9章 業界の買収と戦略的提携

  • 買収
  • 戦略的提携

第10章 癌診断市場

  • 成長を推進する力
  • COVID-19の癌診断市場への影響
  • 癌市場
  • 次世代癌診断市場:癌の部位別
  • 膀胱癌
  • 脳癌
  • 乳癌
  • 大腸癌
  • 婦人科癌
  • 原発不明の癌
  • 胃癌
  • 血液癌
  • 腎臓癌
  • 肝臓癌
  • 肺癌
  • 黒色腫
  • 汎癌
  • 膵臓癌
  • 前立腺癌
  • 甲状腺癌
  • 次世代の癌診断の市場:分析目的別
  • スクリーニング/早期発見市場
  • 診断市場
  • 治療指導市場
  • 監視市場
  • 次世代癌診断市場:テストプラットフォーム別
  • PCRテストプラットフォーム
  • NGSテストプラットフォーム
  • アレイ/マイクロフルイディクステストプラットフォーム
  • セルおよび/またはEVキャプチャテストプラットフォーム
  • マルチプレックス従来型テストプラットフォーム
  • 検査プラットフォーム市場:癌の部位別
  • PCRテストプラットフォーム
  • NGSテストプラットフォーム
  • 診断セグメント別の市場
  • スクリーニング/早期発見市場
  • 診断市場
  • 監視市場
  • 治療指導市場
  • 乳癌診断
  • 大腸癌の診断
  • 肺癌診断
  • 汎癌診断
  • 前立腺癌診断
  • 地域市場分析

第11章 特許

  • 循環腫瘍細胞の特許
  • エキソソーム特許
  • 無細胞DNA(cfDNA)特許
  • バイオマーカー関連の特許
  • 特許の考慮事項:癌診断におけるAI

第12章 企業プロファイル

  • 20/20 GENE SYSTEMS
  • ABBOTT LABORATORIES
  • ADAPTIVE BIOTECHNOLOGIES INC.
  • AGENDIA NV
  • AGILENT TECHNOLOGIES INC.
  • AKADEUM LIFE SCIENCES
  • AMBRY GENETICS
  • AMOY DIAGNOSTICS CO. LTD.
  • ANGLE PLC
  • APOCELL INC.
  • APOSTLE INC.
  • ARBOR VITA CORP.
  • ARCHER DX
  • AROCELL AB
  • ARUP LABORATORIES
  • ASPIRA LABS
  • ASURAGEN, INC.
  • ATILA BIOSYSTEMS
  • AVIVA BIOSCIENCES
  • BECTON, DICKINSON AND CO.
  • BGI SHENZHEN
  • BIOCARTIS NV
  • BIOCEPT INC.
  • BIODESIX INC.
  • BIOFIDELITY LTD.
  • BIOFLUIDICA INC.
  • BIOLIDICS LTD.
  • BIOLOGICAL DYNAMICS INC.
  • BIOPROGNOS SL
  • BIOTHERANOSTICS INC.
  • BIO-TECHNE CORP.
  • BLUESTAR GENOMICS INC.
  • CANCER GENETICS INC.
  • CARIS LIFE SCIENCES
  • CASTLE BIOSCIENCES INC.
  • CC DIAGNOSTICS BV
  • CELCUITY INC.
  • CELLMAX LIFE
  • CELLULAR ANALYTICS
  • CELL MICROSYSTEMS INC.
  • CELSEE DIAGNOSTICS
  • CHIP DIAGNOSTICS
  • CHRONIX BIOMEDICAL
  • CIRCULOGENE THERANOSTICS
  • CLINICAL GENOMICS TECHNOLOGIES
  • CODIAK BIOSCIENCES
  • DANAHER CORP.
  • DECIPHER BIOSCIENCES
  • DERMTECH
  • DIACARTA INC.
  • DNALYTICS
  • EPIGENOMICS AG
  • EPIC SCIENCES INC.
  • EXACT SCIENCES CORP.
  • FLUXION BIOSCIENCES INC.
  • FREENOME INC.
  • FULGENT GENETICS INC.
  • GENECENTRIC THERAPEUTICS
  • GENEDX INC.
  • GENERA BIOSYSTEMS
  • GENESEQ BIOSCIENCES PTY LTD.
  • GENETRON HEALTH TECHNOLOGIES INC.
  • GENEOSCOPY LLC
  • GENEXOSOME TECHNOLOGIES INC.
  • GRAIL INC.
  • GUARDANT HEALTH INC.
  • HOLOGIC INC.
  • HTG MOLECULAR DIAGNOSTICS INC.
  • IDL BIOTECH
  • ILLUMINA INC.
  • IMMUNIS AI
  • INCELLDX INC.
  • INIVATA LTD.
  • INTERPACE BIOSCIENCES INC.
  • INVITAE INC.
  • INVIVOSCRIBE INC.
  • JBS SCIENCE INC.
  • LABORATORY CORP. OF AMERICA INC.
  • LEXENT BIO INC.
  • LUCENCE DIAGNOSTICS PTE. LTD.
  • LUNGLIFE AI, INC.
  • MDNA LIFE SCIENCES INC.
  • MDXHEALTH INC.
  • MEDGENOME INC.
  • MENARINI SILICON BIOSYSTEMS SPA
  • MIRADX
  • MIR SCIENTIFIC
  • MUTANTDX
  • MY PERSONAL THERAPEUTICS LTD.
  • MYRIAD GENETICS INC.
  • NEOGENOMICS LABORATORIES
  • NEO NEW ONCOLOGY GMBH
  • NODEXUS
  • NOVIGENIX SA
  • NRICH DX
  • NUCLEIX
  • NUPROBE INC.
  • ONCIMMUNE HOLDINGS PLC
  • ONCOCYTE CORP.
  • ONCODNA S.A.
  • OPKO HEALTH
  • OXFORD GENE TECHNOLOGY
  • PACIFIC EDGE LTD.
  • PANGAEA LABORATORY
  • PANGAEA ONCOLOGY
  • PERSONAL GENOME DIAGNOSTICS INC.
  • POLYMEDCO, INC.
  • PREDICINE INC.
  • PROVISTA DIAGNOSTICS INC.
  • QIAGEN NV
  • QUANTUMDX
  • QUEST DIAGNOSTICS INC.
  • RARECYTE INC.
  • RESOLUTION BIOSCIENCE INC.
  • ROCHE HOLDING AG
  • SAGA DIAGNOSTICS AB
  • SANOMICS LTD.
  • SIENNA CANCER DIAGNOSTICS LTD.
  • SINGLERA GENOMICS INC.
  • SISTEMAS GENOMICOS
  • SKYLINEDX BV
  • STAGE ZERO LIFE SCIENCES
  • STRAND LIFE SCIENCES PVT., LTD.
  • SYSMEX INOSTICS GMBH
  • THERMO FISHER SCIENTIFIC INC.
  • THRIVE EARLIER DETECTION CORP.
  • TIZIANA LIFE SCIENCES PLC
  • VORTEX BIOSCIENCES
  • VERACYTE
  • VOLITIONRX
  • XING TECHNOLOGIES LLC
  • YIKON GENOMICS CO. LTD.
図表

List of Tables

  • Summary Table: Global Market for Next Generation Cancer Diagnostics, by Cancer Site, Through 2025
    • Table 1: Next Generation Cancer Diagnostics: Scope of Report
    • Table 2: Large-Scale Initiatives: Cancer Diagnostics Industry
    • Table 3: Global Market for Next Generation Cancer Diagnostics, by Technology Platform, Through 2025
    • Table 4: Key Trends in the Market for Next Generation Cancer Diagnostics
    • Table 5: Next Generation Cancer Diagnostics Industry Subsectors
    • Table 6: Diagnostic Market Segments
    • Table 7: Next Generation Diagnostics: Key Analysis Platforms
    • Table 8: Analysis Platforms and Biomarker Types
    • Table 9: DNA Microarray Technologies in Cancer Diagnostics
    • Table 10: Design Features of Protein Microarray Technologies
    • Table 11: Microfluidic LOAC Types Used in Cancer Diagnostics
    • Table 12: Advanced Sequencing Technologies
    • Table 13: Illumina Next Generation Sequencing Workflow
    • Table 14: Thermo Fisher Scientific's Next Generation Sequencing Workflow
    • Table 15: Main Ingredients of PCR Technology
    • Table 16: PCR Process
    • Table 17: Advantages of Droplet Digital PCR for Single-Cell Analysis
    • Table 18: Liquid Biopsy Biomarker Classes
    • Table 19: Cancer Genomic Sequencing and Liquid Biopsy
    • Table 20: Single-Cell Analysis to Identify Cancer Driver Mutations
    • Table 21: Genomics-Based Oncology Workflow
    • Table 22: Unique Challenges: CTC Capture and Analysis
    • Table 23: CTC Workflow
    • Table 24: Cell Differentiators
    • Table 25: Cell Isolation Technologies
    • Table 26: CTC Sample Preparation Technologies
    • Table 27: Single-Cell Analysis Technologies
    • Table 28: Estimated Annual Solid Biopsy Procedures, U.S., Selected Cancers
    • Table 29: Main Risks of Needle-Based Tissue Biopsies
    • Table 30: Factors in Tissue Biopsy
    • Table 31: Approaches to Avatar-Driven Cancer Diagnostics
    • Table 32: R&D: Next Generation Cancer Diagnostics
    • Table 33: Single-Cell Core Research Facilities
    • Table 34: Population Sequencing Projects
    • Table 35: Bladder Cancer Diagnostic Tests, 2020
    • Table 36: Brain Cancer: Next Generation Diagnostics Tests, 2020
    • Table 37: Annual Breast Cancer Treatment Decisions, U.S., by Cancer Classification, 2020
    • Table 38: Breast Cancer MDx Technology Platforms, 2020
    • Table 39: Next Generation Breast Cancer Tests, 2020
    • Table 40: Next Generation Human Papilloma Virus and Cervical Cancer Screening and Genotyping Tests, 2020
    • Table 41: Ovarian Cancer Early Screening Formats, 2020
    • Table 42: Ovarian Cancer: Next Generation Diagnostics Tests, 2020
    • Table 43: CRC Screening Tests, 2020
    • Table 44: Colorectal Cancer: Next Generation Diagnostic Tests, 2020
    • Table 45: Cancer Unknown Primary: Next Generation Diagnostic Tests, 2020
    • Table 46: Gastric Cancer: Next Generation Diagnostic Tests, 2020
    • Table 47: Kidney Cancer: Next Generation Diagnostic Tests, 2020
    • Table 48: Leukemia and Myeloma: Next Generation Diagnostic Tests, 2020
    • Table 49: Liver Cancer: Next Generation Diagnostic Tests, 2020
    • Table 50: Five-Year Survival Rates for Non-Small Cell Lung Cancer, 2020
    • Table 51: Lung Cancer: Next Generation Diagnostic Tests, 2020
    • Table 52: Lymphoma: Next Generation Diagnostic Tests, 2020
    • Table 53: Melanoma: Next Generation Diagnostic Tests, 2020
    • Table 54: Pan-Cancer: Next Generation Diagnostic Tests, 2020
    • Table 55: Prostate Cancer Next Generation Diagnostic Tests, 2020
    • Table 56: Thyroid Cancer: Next Generation Diagnostics Tests, 2020
    • Table 57: Advanced Sequencing Industry Company Positioning
    • Table 58: End-to-End Sequencing Approaches
    • Table 59: Long-Read Sequencing Industry
    • Table 60: Sequencing Informatics Industry
    • Table 61: PCR Companies
    • Table 62: Advantages of Droplet Digital PCR for Single-Cell Analysis
    • Table 63: Digital PCR Liquid Biopsy Industry
    • Table 64: CTC Separations Industry
    • Table 65: Liquid Biopsy Assay Industry: Company Focus
    • Table 66: NGS-Based Liquid Biopsy Market Differentiation
    • Table 67: Cancer Diagnostics Industry Acquisitions, Jan. 2019-July 2020
    • Table 68: Cancer Diagnostics Strategic Alliances, Jan. 2019-July 2020
    • Table 69: Liquid Biopsy: Forces Driving Growth, 2020
    • Table 70: Limitations of Solid Biopsy in Cancer Applications
    • Table 71: Low-Frequency Mutation Detection
    • Table 72: Global Market for Next Generation Cancer Diagnostics, by Cancer Site, Through 2025
    • Table 73: Ovarian Cancer: Five-Year Survival Rate
    • Table 74: NIH Liquid Biopsy Early Detection Initiative
    • Table 75: Global Market for Next Generation Cancer Diagnostics, by Purpose of Analysis, Through 2025
    • Table 76: MRI and Liquid Biopsy Methods
    • Table 77: Early Detection: Tissue of Origin Approaches
    • Table 78: Global Market for Next Generation Cancer Diagnostics, by Test Platform, Through 2025
    • Table 79: FDA-Approved or CE-Marked Tests with Epigenetic Component
    • Table 80: Global Market for PCR-Based Cancer Diagnostics, by Cancer Site, Through 2025
    • Table 81: Global Market for NGS-Based Cancer Diagnostics, by Cancer Site, Through 2025
    • Table 82: Global Market for Next Generation Cancer Screening/Early Detection, by Cancer Site, Through 2025
    • Table 83: Global Market for Next Generation Cancer Diagnosis, by Cancer Site, Through 2025
    • Table 84: Global Market for Next Generation Cancer Monitoring, by Cancer Site, Through 2025
    • Table 85: Global Market for Next Generation Cancer Therapy Guidance, by Cancer Site, Through 2025
    • Table 86: Global Market for Breast Cancer Diagnostics, by Analysis Method, Through 2025
    • Table 87: Global Market for Colorectal Cancer Diagnostics, by Analysis Method, Through 2025
    • Table 88: Global Market for Lung Cancer Diagnostics, by Analysis Method, Through 2025
    • Table 89: Global Market for Pan-Cancer Diagnostics, by Analysis Method, Through 2025
    • Table 90: Global Market for Prostate Cancer Diagnostics, by Analysis Method, Through 2025
    • Table 91: Global Market for Next Generation Cancer Diagnostics, by Region, Through 2025
    • Table 92: Patent Activity: Circulating Tumor Cells (CTCs), by Region, Jan. 2010-June 2020
    • Table 93: Patent Activity: Exosomes, by Region, Jan. 2010-June 2020
    • Table 94: Patent Activity: cfDNA, by Region, 2010-June 2020
    • Table 95: Patent Activity: Cancer Biomarkers, by Region, Jan. 2010-June 2020

List of Figures

  • Summary Figure: Global Market for Next Generation Cancer Diagnostics, by Cancer Site, 2019-2025
目次
Product Code: BIO081C

Highlights:

The global market for next generation cancer diagnostics is expected to grow from $6.2 billion in 2020 to $16.7 billion by 2025 with a compound annual growth rate (CAGR) of 21.9% for the period of 2020-2025.

Next generation digestive systems cancer diagnostics market is expected to grow from $1.5 billion in 2020 to $4.5 billion by 2025 with a compound annual growth rate (CAGR) of 24.5% for the period of 2020-2025.

Next generation breast cancer diagnostics market is expected to grow from $1.6 billion in 2020 to $3.1 billion by 2025 with a compound annual growth rate (CAGR) of 13.9% for the period of 2020-2025.

Report Scope:

The scope of this report includes next generation diagnostic technologies, applications, industry subsegments, major funding initiatives, patents and companies. The market sizes for next generation cancer diagnostics are given for 2019, 2020 (estimated) and 2025 (forecasted).

This report reviews the main next generation diagnostic technologies, including next generation sequencing (NGS), polymerase chain reaction (PCR), multiplex conventional, cell or extracellular vesicle capture and arrays/microfluidics. The report also discusses, in-depth, various liquid biopsy platforms and how these compare with tissue-based testing.

The report discusses several significant, large-scale research initiatives that contribute to cancer diagnostic development. Key forces driving the market are enumerated.

The structures of several important industry subsectors are reviewed, as well as major industry acquisitions and strategic alliances from Jan. 2019 through June 2020. The industry subsectors analyzed include DNA sequencing instruments, long-read DNA sequencing, informatics, PCR, droplet digital PCR, CTC capture and detection and liquid biopsy.

The market for next generation cancer diagnostics is analyzed in depth. The market is analyzed by cancer site (bladder, brain, breast, colorectal, cancer of unknown primary, gastric, gynecologic, hematologic, kidney, liver, lung, pan-cancer, pancreatic, prostate, melanoma and thyroid), by test purpose (screening/early detection, diagnosis, monitoring, therapy guidance), by test platform (arrays/microfluidics, cell/EV capture, multiplex conventional, PCR and NGS) and by geography (North America, Europe, Asia Pacific, Rest of World).

Market data covers 2019, 2020 (estimated) and 2025 (forecasted).

There is a special section discussing the impact of COVID-19 on the market for next generation cancer diagnostics.

More than 130 companies in the next generation cancer diagnostics industry are profiled in this report.

BCC Research provides a summary of the main industry acquisitions and strategic alliances from Jan. 2019 through June 2020, including key alliance trends.

Report Includes:

  • 22 data tables and 74 additional tables
  • An overview of the global market and technologies for next generation cancer diagnostics
  • Analyses of global market trends, with data from 2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2025
  • Analyses of the next generation cancer diagnostics market by cancer site, analysis purpose, analysis platform and region
  • Discussion on arrays and microfluidics (LOAC) technologies, multiplex conventional technologies, next generation sequencing technology and polymerase chain reaction (PCR) technology
  • Evaluation of current market trends, market size, market forecast, pipeline analysis of new products, and regulatory scenarios of the cancer diagnostics market
  • Discussion on factors affecting the market including cancer diagnostics needs, regulatory trends, industry structure, and patent statuses
  • Details of the key initiatives and programs related to the next generation cancer diagnostics market
  • Market share analysis of the key companies of the industry, their strategic profiling, competitive landscape, and their detailed company profiles, including Abbott Laboratories, Illumina Inc., Myriad Genetics Inc., Qiagen NV, Oche Holding AG, and Thermo Fisher Scientific Inc.

Table of Contents

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Overview

  • Large-Scale Initiatives and Consortia
  • Market Size
  • Liquid Biopsy as a Market Driving Force
  • Key Trends
  • Industry

Chapter 4 Technologies

  • Diagnostics Overview
  • Arrays and Microfluidics (LOAC) Technologies
  • DNA Microarrays
  • Protein Microarrays
  • Microfluidics
  • Multiplex Conventional Technologies
  • Next Generation Sequencing Technology
  • Polymerase Chain Reaction (PCR) Technology

Chapter 5 Liquid Biopsy Technologies

  • Liquid Biopsy Biomarkers
  • Cancer Genomics
  • Circulating Tumor Cell Technologies
  • CTC Workflow
  • Cell Isolation Technologies
  • CTC Sample Preparation Technologies
  • CTC Downstream Analysis Technologies
  • Comparison of Liquid Biopsy with Conventional Biopsy
  • Cancer Testing
  • Avatar-Driven Diagnostic Approaches

Chapter 6 Next Generation Cancer Diagnostics: Key Initiatives and Programs

  • Blood Profiling Atlas
  • Cancer-ID
  • Cancer Moon Shots
  • China Precision Medicine Initiative
  • ClinGen
  • CTC Trap Consortium
  • Early Cancer Detection Consortium
  • EpiFemCare
  • France Genomic Medicine Plan
  • Friends of Cancer Research Project
  • Human Cell Atlas
  • Immunomonitor Consortium
  • Integration of Imaging and Fluid-Based Tumor Monitoring
  • Liquid Biopsies and Imaging for Improved Cancer Care
  • Million Veteran Program
  • MedSeq
  • Next-Generation Single-Cell Analysis Program
  • Population Sequencing Projects
  • Precancer Atlas
  • Precision Medicine Initiative
  • Prompt
  • QuIP Project
  • Single-Cell Proteomics and Lipidomics Project
  • TopMed
  • Treehouse Childhood Cancer Initiative
  • Very Rare Cancer Consortium
  • Worldwide Innovative Networking (WIN) Consortium
  • Single-Cell Research
  • Cambridge Single-Cell Analysis Core Facility
  • Harvard Medical School Single-Cell Core
  • Mayo Medical Genome Facility
  • National Center for Single-Cell Biology
  • Single-Cell Analysis Core
  • UC San Francisco Single-Cell Analysis Center
  • Population Sequencing Programs

Chapter 7 Next Generation Cancer Diagnostic Applications by Cancer Site

  • Introduction
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Breast Cancer Screening
  • Prognosis and Pharmacogenetics Tests
  • Breast Cancer MDx Platforms
  • Status of Next Generation Breast Cancer Tests
  • Breast Cancer Early Detection and Screening Tests
  • Breast Cancer Risk Tests
  • Response to Chemotherapy, Recurrence Probability and Subtyping
  • Gynecologic Cancers
  • Cervical Cancer
  • Ovarian Cancer
  • Colorectal Cancer
  • Conventional Colorectal Cancer Screening Tests
  • Next Generation Colorectal Cancer Diagnostic Tests
  • Cancer Unknown Primary
  • Gastric Cancer
  • Kidney Cancer
  • Hematologic Tests: Leukemia and Myeloma
  • Liver Cancer
  • Lung Cancer
  • Hematologic Tests: Lymphomas
  • Melanoma
  • Pan-Cancer
  • Prostate Cancer
  • Thyroid Cancer

Chapter 8 Cancer Diagnostics Industries

  • Sequencing Instruments Industry
  • Long Read Sequencing Industry
  • Sequencing Informatics Industry
  • PCR Industry
  • Droplet Digital PCR Industry
  • CTC Capture and Detection Industry
  • Liquid Biopsy Assay Industry

Chapter 9 Industry Acquisitions and Strategic Alliances

  • Acquisitions
  • Strategic Alliances

Chapter 10 Cancer Diagnostics Markets

  • Forces Driving Growth
  • COVID-19 Impact on Cancer Diagnostic Markets
  • Cancer Markets
  • Market for Next Generation Cancer Diagnostics by Cancer Site
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Gynecologic Cancers
  • Cancer of Unknown Primary
  • Gastric Cancer
  • Hematologic Cancers
  • Kidney Cancer
  • Liver Cancer
  • Lung Cancer
  • Melanoma
  • Pan-Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Thyroid Cancer
  • Market for Next Generation Cancer Diagnostics by Purpose of Analysis
  • Screening/Early Detection Market
  • Diagnosis Market
  • Therapy Guidance Market
  • Monitoring Market
  • Market for Next Generation Cancer Diagnostics by Test Platform
  • PCR Test Platform
  • NGS Test Platform
  • Array/Microfluidics Test Platform
  • Cells and/or EV Capture Test Platform
  • Multiplex Conventional Test Platform
  • Market for Test Platforms by Cancer Site
  • PCR Test Platform
  • NGS Test Platform
  • Market by Diagnostic Segment
  • Screening/Early Detection Market
  • Diagnostics Market
  • Monitoring Market
  • Therapy Guidance Market
  • Breast Cancer Diagnostics
  • Colorectal Cancer Diagnostics
  • Lung Cancer Diagnostics
  • Pan-Cancer Diagnostics
  • Prostate Cancer Diagnostics
  • Regional Market Analysis

Chapter 11 Patents

  • Circulating Tumor Cell Patents
  • Exosome Patents
  • Cell-free DNA (cfDNA) Patents
  • Biomarker-Related Patents
  • Patent Considerations: AI in Cancer Diagnostics

Chapter 12 Company Profiles

  • 20/20 GENE SYSTEMS
  • ABBOTT LABORATORIES
  • ADAPTIVE BIOTECHNOLOGIES INC.
  • AGENDIA NV
  • AGILENT TECHNOLOGIES INC.
  • AKADEUM LIFE SCIENCES
  • AMBRY GENETICS
  • AMOY DIAGNOSTICS CO. LTD.
  • ANGLE PLC
  • APOCELL INC.
  • APOSTLE INC.
  • ARBOR VITA CORP.
  • ARCHER DX
  • AROCELL AB
  • ARUP LABORATORIES
  • ASPIRA LABS
  • ASURAGEN, INC.
  • ATILA BIOSYSTEMS
  • AVIVA BIOSCIENCES
  • BECTON, DICKINSON AND CO.
  • BGI SHENZHEN
  • BIOCARTIS NV
  • BIOCEPT INC.
  • BIODESIX INC.
  • BIOFIDELITY LTD.
  • BIOFLUIDICA INC.
  • BIOLIDICS LTD.
  • BIOLOGICAL DYNAMICS INC.
  • BIOPROGNOS SL
  • BIOTHERANOSTICS INC.
  • BIO-TECHNE CORP.
  • BLUESTAR GENOMICS INC.
  • CANCER GENETICS INC.
  • CARIS LIFE SCIENCES
  • CASTLE BIOSCIENCES INC.
  • CC DIAGNOSTICS BV
  • CELCUITY INC.
  • CELLMAX LIFE
  • CELLULAR ANALYTICS
  • CELL MICROSYSTEMS INC.
  • CELSEE DIAGNOSTICS
  • CHIP DIAGNOSTICS
  • CHRONIX BIOMEDICAL
  • CIRCULOGENE THERANOSTICS
  • CLINICAL GENOMICS TECHNOLOGIES
  • CODIAK BIOSCIENCES
  • DANAHER CORP.
  • DECIPHER BIOSCIENCES
  • DERMTECH
  • DIACARTA INC.
  • DNALYTICS
  • EPIGENOMICS AG
  • EPIC SCIENCES INC.
  • EXACT SCIENCES CORP.
  • FLUXION BIOSCIENCES INC.
  • FREENOME INC.
  • FULGENT GENETICS INC.
  • GENECENTRIC THERAPEUTICS
  • GENEDX INC.
  • GENERA BIOSYSTEMS
  • GENESEQ BIOSCIENCES PTY LTD.
  • GENETRON HEALTH TECHNOLOGIES INC.
  • GENEOSCOPY LLC
  • GENEXOSOME TECHNOLOGIES INC.
  • GRAIL INC.
  • GUARDANT HEALTH INC.
  • HOLOGIC INC.
  • HTG MOLECULAR DIAGNOSTICS INC.
  • IDL BIOTECH
  • ILLUMINA INC.
  • IMMUNIS AI
  • INCELLDX INC.
  • INIVATA LTD.
  • INTERPACE BIOSCIENCES INC.
  • INVITAE INC.
  • INVIVOSCRIBE INC.
  • JBS SCIENCE INC.
  • LABORATORY CORP. OF AMERICA INC.
  • LEXENT BIO INC.
  • LUCENCE DIAGNOSTICS PTE. LTD.
  • LUNGLIFE AI, INC.
  • MDNA LIFE SCIENCES INC.
  • MDXHEALTH INC.
  • MEDGENOME INC.
  • MENARINI SILICON BIOSYSTEMS SPA
  • MIRADX
  • MIR SCIENTIFIC
  • MUTANTDX
  • MY PERSONAL THERAPEUTICS LTD.
  • MYRIAD GENETICS INC.
  • NEOGENOMICS LABORATORIES
  • NEO NEW ONCOLOGY GMBH
  • NODEXUS
  • NOVIGENIX SA
  • NRICH DX
  • NUCLEIX
  • NUPROBE INC.
  • ONCIMMUNE HOLDINGS PLC
  • ONCOCYTE CORP.
  • ONCODNA S.A.
  • OPKO HEALTH
  • OXFORD GENE TECHNOLOGY
  • PACIFIC EDGE LTD.
  • PANGAEA LABORATORY
  • PANGAEA ONCOLOGY
  • PERSONAL GENOME DIAGNOSTICS INC.
  • POLYMEDCO, INC.
  • PREDICINE INC.
  • PROVISTA DIAGNOSTICS INC.
  • QIAGEN NV
  • QUANTUMDX
  • QUEST DIAGNOSTICS INC.
  • RARECYTE INC.
  • RESOLUTION BIOSCIENCE INC.
  • ROCHE HOLDING AG
  • SAGA DIAGNOSTICS AB
  • SANOMICS LTD.
  • SIENNA CANCER DIAGNOSTICS LTD.
  • SINGLERA GENOMICS INC.
  • SISTEMAS GENOMICOS
  • SKYLINEDX BV
  • STAGE ZERO LIFE SCIENCES
  • STRAND LIFE SCIENCES PVT., LTD.
  • SYSMEX INOSTICS GMBH
  • THERMO FISHER SCIENTIFIC INC.
  • THRIVE EARLIER DETECTION CORP.
  • TIZIANA LIFE SCIENCES PLC
  • VORTEX BIOSCIENCES
  • VERACYTE
  • VOLITIONRX
  • XING TECHNOLOGIES LLC
  • YIKON GENOMICS CO. LTD.
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.